Evidence that Tenecteplase Is Noninferior to Alteplase i

Stroke

50, 2156-2162

DOI: 10.1161/strokeaha.119.025080

Citation Report

#	Article	IF	CITATIONS
1	Efficacy and Safety of Intravenous Thrombolysis in Patients with Unknown Onset Stroke: A Meta-Analysis. Behavioural Neurology, 2019, 2019, 1-11.	2.1	6
2	Management of Acute Ischemic Stroke. Critical Care Medicine, 2020, 48, 1654-1663.	0.9	316
3	Tenecteplase Thrombolysis for Acute Ischemic Stroke. Stroke, 2020, 51, 3440-3451.	2.0	101
4	Stroke Thrombolysis With Tenecteplase to Reduce Emergency Department Spread of Coronavirus Disease 2019 and Shortages of Alteplase. JAMA Neurology, 2020, 77, 1203.	9.0	42
5	Ischemic stroke and cerebral venous sinus thrombosis in pregnancy. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2020, 172, 3-31.	1.8	17
6	Tenecteplase for Acute Ischemic Stroke: Current Evidence and Practical Considerations. CNS Drugs, 2020, 34, 1009-1014.	5.9	5
7	Tenecteplase (and common sense) in short supply during the <scp>COVID</scp> â€19 pandemic. Medical Journal of Australia, 2020, 213, 442.	1.7	4
8	Thrombolysis for Central Retinal Artery Occlusion in 2020: Time Is Vision!. Journal of Neuro-Ophthalmology, 2020, 40, 333-345.	0.8	49
9	Efficacy and safety of different doses of tenecteplase for the treatment of acute ischemic stroke. Medicine (United States), 2020, 99, e23379.	1.0	1
10	Using Tenecteplase for Acute Ischemic Stroke: What Is the Hold Up?. Western Journal of Emergency Medicine, 2020, 21, 199-202.	1.1	16
11	Dabigatran Reversal Before Intravenous Tenecteplase in Acute Ischemic Stroke. Stroke, 2020, 51, 1616-1619.	2.0	19
12	Stroke. Lancet, The, 2020, 396, 129-142.	13.7	533
13	3K3A-Activated Protein C Variant Does Not Interfere With the Plasma Clot Lysis Activity of Tenecteplase. Stroke, 2020, 51, 2236-2239.	2.0	1
14	Effect of Intravenous Tenecteplase Dose on Cerebral Reperfusion Before Thrombectomy in Patients With Large Vessel Occlusion Ischemic Stroke. JAMA - Journal of the American Medical Association, 2020, 323, 1257.	7.4	168
15	Management of acute ischemic stroke. BMJ, The, 2020, 368, l6983.	6.0	305
16	Wake-up Stroke: New Opportunities for Acute Stroke Treatment. Current Emergency and Hospital Medicine Reports, 2020, 8, 16-24.	1.5	O
17	Acute ischemic stroke management: concepts and controversies. A narrative review. Expert Review of Neurotherapeutics, 2021, 21, 65-79.	2.8	16
18	Intravenous Thrombolysis With Tenecteplase in Patients With Large Vessel Occlusions. Stroke, 2021, 52, 308-312.	2.0	67

#	ARTICLE	IF	CITATIONS
19	Prevalence of intravenous thrombolysis for hyperacute ischemic stroke. Japanese Journal of Thrombosis and Hemostasis, 2021, 32, 264-270.	0.1	O
20	Intravenous Thrombolysis Before Endovascular Thrombectomy for Acute Ischemic Stroke. JAMA - Journal of the American Medical Association, 2021, 325, 229.	7.4	25
21	Off-label use of intravenous thrombolysis for acute ischemic stroke: a critical appraisal of randomized and real-world evidence. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642199736.	<b>3.</b> 5	26
22	Development and Testing of Thrombolytics in Stroke. Journal of Stroke, 2021, 23, 12-36.	3.2	14
23	Neuroprotection Following Stroke. , 2021, , .		0
24	Tenecteplase in wake-up ischemic stroke trial: Protocol for a randomized-controlled trial. International Journal of Stroke, 2021, 16, 990-994.	5.9	20
25	European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke. European Stroke Journal, 2021, 6, I-LXII.	5.5	500
26	Ongoing Advances in Medical and Interventional Treatments of Large Vessel Occlusion Stroke. Stroke, 2021, 52, 1115-1117.	2.0	2
27	Routine Use of Tenecteplase for Thrombolysis in Acute Ischemic Stroke. Stroke, 2021, 52, 1087-1090.	2.0	48
28	Should Tenecteplase Replace Alteplase for Acute Thrombolysis?. Stroke, 2021, 52, 1091-1093.	2.0	7
29	Diagnosis and Management of Transient Ischemic Attack and Acute Ischemic Stroke. JAMA - Journal of the American Medical Association, 2021, 325, 1088.	7.4	277
30	Early Experience With Tenecteplase at a Comprehensive Stroke Center. Neurology: Clinical Practice, 2021, 11, e885-e889.	1.6	2
31	Tenecteplase for thrombolysis in stroke patients: Systematic review with meta-analysis. American Journal of Emergency Medicine, 2021, 42, 31-37.	1.6	23
32	An update on hyper-acute management of ischaemic stroke. Clinical Medicine, 2021, 21, 215-221.	1.9	7
33	Emergency Care of Patients with Acute Ischemic Stroke. Neurologic Clinics, 2021, 39, 391-404.	1.8	10
34	Direct mechanical thrombectomy without intravenous thrombolysis versus bridging therapy for acute ischemic stroke: A meta-analysis of randomized controlled trials. International Journal of Stroke, 2021, 16, 621-631.	<b>5.</b> 9	36
35	Utility of Intravenous Alteplase Prior to Endovascular Stroke Treatment. Neurology, 2021, 97, e777-e784.	1.1	29
36	Current treatment for childhood arterial ischaemic stroke. The Lancet Child and Adolescent Health, 2021, 5, 825-836.	<b>5.</b> 6	16

#	Article	IF	CITATIONS
37	Endovascular thrombectomy without versus with intravenous thrombolysis in acute ischemic stroke: a non-inferiority meta-analysis of randomized clinical trials. Journal of NeuroInterventional Surgery, 2022, 14, 227-232.	3.3	40
38	Safety and efficacy of tenecteplase versus alteplase in patients with acute ischaemic stroke (TRACE): a multicentre, randomised, open label, blinded-endpoint (PROBE) controlled phase II study. Stroke and Vascular Neurology, 2022, 7, 47-53.	3.3	37
39	Tenecteplase Reperfusion therapy in Acute ischaemic Cerebrovascular Events-II (TRACE II): rationale and design. Stroke and Vascular Neurology, 2022, 7, 71-76.	3.3	7
40	Tenecteplase Thrombolysis in Posterior Circulation Stroke. Frontiers in Neurology, 2021, 12, 678887.	2.4	7
41	Acute Reperfusion Therapies for Acute Ischemic Stroke. Journal of Clinical Medicine, 2021, 10, 3677.	2.4	10
42	Should Tenecteplase be Given in Clinical Practice for Acute Ischemic Stroke Thrombolysis?. Stroke, 2021, 52, 3075-3080.	2.0	7
43	Emerging agents for the treatment and prevention of stroke: progress in clinical trials. Expert Opinion on Investigational Drugs, 2021, 30, 1025-1035.	4.1	13
44	Non-immunogenic recombinant staphylokinase versus alteplase for patients with acute ischaemic stroke 4·5 h after symptom onset in Russia (FRIDA): a randomised, open label, multicentre, parallel-group, non-inferiority trial. Lancet Neurology, The, 2021, 20, 721-728.	10.2	26
45	The past, present, and future of enzyme-based therapies. Drug Discovery Today, 2022, 27, 117-133.	6.4	12
46	Cardio-cerebral infarction in left MCA strokes: a case series and literature review. Neurological Sciences, 2022, 43, 2413-2422.	1.9	9
47	CE: Acute Ischemic Stroke. American Journal of Nursing, 2021, 121, 26-33.	0.4	7
48	Switching to Tenecteplase for Stroke Thrombolysis. Stroke, 2021, 52, e590-e593.	2.0	38
49	Low-cost alternatives for the management of acute ischemic stroke in low and middle-income countries. Annals of Medicine and Surgery, 2021, 72, 102969.	1.1	5
50	Functional Outcome, Recanalization, and Hemorrhage Rates After Large Vessel Occlusion Stroke Treated With Tenecteplase Before Thrombectomy. Neurology, 2021, 97, e2173-e2184.	1.1	24
51	Maintaining stroke care during the COVID-19 pandemic in lower- and middle-income countries: World Stroke Organization Position Statement endorsed by American Stroke Association and American Heart Association. International Journal of Stroke, 2021, , 174749302110558.	5.9	7
52	Acute Treatment of Ischemic Stroke. Neurologic Clinics, 2022, 40, 17-32.	1.8	14
53	Mechanical Thrombectomy with or without Intravenous Thrombolysis in Acute Ischemic Stroke: A Meta-Analysis for Randomized Controlled Trials. European Neurology, 2022, 85, 85-94.	1.4	5
54	Thrombolysis in Acute Stroke. , 0, , .		1

#	Article	IF	CITATIONS
55	Direct Endovascular Thrombectomy Alone vs. Bridging Thrombolysis for Patients with Acute Ischemic Stroke. Clinical Neuroradiology, $2021$ , , $1$ .	1.9	8
56	Tenecteplase Improves Doorâ€toâ€Needle Time in Realâ€World Acute Stroke Treatment. , 2021, 1, .		16
57	A practice game changer: Impact of tenecteplase for acute ischemic stroke in a multicenter quality improvement project. American Journal of Health-System Pharmacy, 2022, 79, e149-e153.	1.0	2
58	Consent Issues in the Management of Acute Ischemic Stroke. Neurology, 2022, 98, 73-79.	1.1	6
59	Maintaining Stroke Care During the COVID-19 Pandemic in Lower- and Middle-Income Countries: World Stroke Organization Position Statement Endorsed by American Stroke Association and American Heart Association. Stroke, 2022, 53, 1043-1050.	2.0	0
60	Tenecteplase in Pulmonary Embolism Patients: A Meta-Analysis and Systematic Review. Frontiers in Medicine, 2022, 9, 860565.	2.6	5
61	Off-Label Use of Tenecteplase for the Treatment of Acute Ischemic Stroke. JAMA Network Open, 2022, 5, e224506.	5.9	44
62	How Frequent is the One-Hour tPA Infusion Interrupted or Delayed?. Journal of Stroke and Cerebrovascular Diseases, 2022, 31, 106471.	1.6	3
63	Intravenous thrombolysis prior to mechanical thrombectomy does not affect clinical or procedural outcomes in patients with large vessel occlusion acute ischemic stroke. Journal of Clinical Neuroscience, 2022, 100, 120-123.	1,5	2
64	Efficacy and Safety of Recombinant Human Prourokinase in Acute Ischemic Stroke: A Phase Ila Randomized Clinical Trial. Translational Stroke Research, 2022, 13, 995-1004.	4.2	7
65	Tenecteplase in Ischemic Stroke: Challenge and Opportunity. Neuropsychiatric Disease and Treatment, 2022, Volume 18, 1013-1026.	2.2	4
66	The End of Tissue-Type Plasminogen Activator's Reign?. Stroke, 2022, , 101161STROKEAHA122039287.	2.0	5
67	Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2,) Tj ETQq0 (The, 2022, 21, 511-519.	0 0 rgBT /0 10.2	Overlock 10 T 88
69	Neuroprotection in Acute Ischemic Stroke: A Battle Against the Biology of Nature. Frontiers in Neurology, 0, 13, .	2.4	19
70	<scp>Intravenous</scp> Thrombolysis with Tenecteplase for the Treatment of Acute Ischemic Stroke. Annals of Neurology, 2022, 92, 349-357.	5.3	16
71	Tenecteplase and alteplase for thrombolysis of acute ischemic stroke within 4.5 hours: An efficacy and safety study. Annals of Indian Academy of Neurology, 2022, 25, 897.	0.5	3
72	A Novel Mobilization Criteria Checklist 12 to 24 Hours After Intravenous Thrombolysis in Acute Ischemic Stroke. Journal of Acute Care Physical Therapy, 0, Publish Ahead of Print, .	0.2	0
73	Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial. Lancet, The, 2022, 400, 161-169.	13.7	151

#	Article	IF	CITATIONS
75	Treatment times, functional outcome, and hemorrhage rates after switching to tenecteplase for stroke thrombolysis: Insights from the TETRIS registry. European Stroke Journal, 2022, 7, 358-364.	5.5	14
76	Modeling the potential efficiency of a blood biomarker-based tool to guide pre-hospital thrombolytic therapy in stroke patients. European Journal of Health Economics, 2023, 24, 621-632.	2.8	1
77	Tenecteplase or Alteplase: What Is the Thrombolytic Agent of the Future?. Current Treatment Options in Neurology, 2022, 24, 503-513.	1.8	9
78	Composition and Organization of Acute Ischemic Stroke Thrombus: A Wealth of Information for Future Thrombolytic Strategies. Frontiers in Neurology, 0, 13, .	2.4	7
79	Current advances in ischemic stroke management. Journal of Education, Health and Sport, 2022, 12, 644-649.	0.1	0
80	Major Bleeding Postadministration of Tenecteplase Versus Alteplase in Acute Ischemic Stroke. Annals of Pharmacotherapy, 2023, 57, 535-543.	1.9	1
81	IV tenecteplase: A non-inferior alternative to alteplase?. Med, 2022, 3, 519-520.	4.4	1
82	Effectiveness and Safety of Tecneplase vs. Alteplase in the Acute Treatment of Ischemic Stroke. Journal of Personalized Medicine, 2022, 12, 1525.	2.5	3
83	Ischemic Stroke. , 2022, , 159-172.		0
84	Short-Term Efficacy Outcomes of Tenecteplase versus Alteplase for Acute Ischemic Stroke: A Meta-Analysis of 5 Randomized Trials. Neurology India, 2022, 70, 1454.	0.4	3
85	Tenecteplase or Alteplase Better in Patients with Acute Ischemic Stroke Due to Large Vessel Occlusion: A Single Center Observational Study. Medicina (Lithuania), 2022, 58, 1169.	2.0	4
86	Switching to Tenecteplase from Alteplase for Ischemic Stroke: Is it the Time for Universal Adoption?. Annals of Neurosciences, 0, , 097275312211255.	1.7	0
88	Prospective Observational Cohort Study of Tenecteplase Versus Alteplase in Routine Clinical Practice. Stroke, 2022, 53, 3583-3593.	2.0	24
89	Prevalence, risk factors, and clinical outcomes of remote intracerebral hemorrhage after intravenous thrombolysis in acute ischemic stroke: a systematic review and meta-analysis. Journal of Neurology, 2023, 270, 651-661.	3.6	10
90	Different dosing regimens of Tenecteplase in acute ischemic stroke: A network meta-analysis of the clinical evidence. European Stroke Journal, 2023, 8, 93-105.	5.5	1
91	Tenecteplase in acute ischemic stroke: Review of the literature and expert consensus from the French Neurovascular Society. Revue Neurologique, 2022, , .	1.5	0
92	Association of intravenous thrombolysis and pre-interventional reperfusion: a post hoc analysis of the SWIFT DIRECT trial. Journal of NeuroInterventional Surgery, 2023, 15, e232-e239.	3.3	3
93	Outcomes with IV tenecteplase and IV alteplase for acute ischemic stroke with or without thrombectomy in real-world settings in the United States. Journal of Stroke and Cerebrovascular Diseases, 2023, 32, 106898.	1.6	7

#	Article	IF	CITATIONS
94	The efficacy and safety of tenecteplase versus alteplase for acute ischemic stroke: an updated systematic review, pairwise, and network meta-analysis of randomized controlled trials. Journal of Thrombosis and Thrombolysis, 2023, 55, 322-338.	2.1	13
95	Safety and efficacy of tenecteplase in patients with wake-up stroke assessed by non-contrast CT (TWIST): a multicentre, open-label, randomised controlled trial. Lancet Neurology, The, 2023, 22, 117-126.	10.2	19
96	Tenecteplase in managing acute ischemic stroke: a long-term costâ $\in$ "utility analysis in Iran. Expert Review of Pharmacoeconomics and Outcomes Research, 0, , 1-11.	1.4	3
97	Intravenous Thrombolytics in the Treatment of Acute Ischemic Stroke. Current Treatment Options in Cardiovascular Medicine, 0, , .	0.9	4
98	Building Evidence on Safety of Thrombolysis for Patients Undergoing Direct Oral Anticoagulant Treatment. JAMA Neurology, 0, , .	9.0	0
99	Conversion From Intravenous Alteplase to Tenecteplase for Treatment of Acute Ischemic Stroke Across a Large Community Hospital Health System. Annals of Pharmacotherapy, 2023, 57, 1147-1153.	1.9	2
100	Replacing Alteplase with Tenecteplase: Is the Time Ripe?. Journal of Stroke, 2023, 25, 72-80.	3.2	7
101	Efficacy outcomes of tenecteplase versus alteplase in patients with ischemic stroke in therapeutic window: experience from a single institution. Archives of Medicine and Health Sciences, 2023, 11, 3.	0.1	O
102	Thrombolysis for acute ischaemic stroke: current status and future perspectives. Lancet Neurology, The, 2023, 22, 418-429.	10.2	45
103	Feasibility of switching from alteplase to tenecteplase for stroke thrombolysis – A retrospective cohort analysis. IBRO Neuroscience Reports, 2023, 14, 353-357.	1.6	0
104	European Stroke Organisation (ESO) expedited recommendation on tenecteplase for acute ischaemic stroke. European Stroke Journal, 2023, 8, 8-54.	5.5	26
105	Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial. Lancet, The, 2023, 401, 645-654.	13.7	63
106	Advancements in the management of acute ischemic stroke: A narrative review. Journal of the American College of Emergency Physicians Open, 2023, 4, .	0.7	2
107	Terapi Tissue Plasminogen Activator untuk Stroke Iskemik Akut. , 2023, 50, 167-170.		0
108	Complications of Intravenous Tenecteplase Versus Alteplase for the Treatment of Acute Ischemic Stroke: A Systematic Review and Meta-Analysis. Stroke, 2023, 54, 1192-1204.	2.0	4
109	A Neuro-Informatics Pipeline for Cerebrovascular Disease: Research Registry Development. JMIR Formative Research, 0, 7, e40639.	1.4	O
110	Intravenous Thrombolysis for Acute Ischemic Stroke. CONTINUUM Lifelong Learning in Neurology, 2023, 29, 425-442.	0.8	2
111	Use of Tenecteplase in Acute Ischemic Stroke in the Time of SARS-CoV-2. Neurohospitalist, The, 2023, 13, 266-271.	0.8	1

#	Article	IF	CITATIONS
113	The efficacy and safety of intravenous thrombolysis with tenecteplase versus alteplase for acute ischemic stroke: a systematic review and meta-analysis. Neurological Sciences, 2023, 44, 3005-3015.	1.9	1
114	Endovascular Thrombectomy versus Endovascular Thrombectomy Preceded by Intravenous Thrombolysis: A Systematic Review and Meta-Analysis. World Neurosurgery, 2023, 177, 39-58.	1.3	2
115	Symptomatic Intracranial Hemorrhage With Tenecteplase vs Alteplase in Patients With Acute Ischemic Stroke. JAMA Neurology, 2023, 80, 732.	9.0	11
116	Different doses of tenecteplase vs. alteplase for acute ischemic stroke within 4.5 hours of symptom onset: a network meta-analysis of randomized controlled trials. Frontiers in Neurology, 0, 14, .	2.4	5
117	Evolving Thrombolytics: from Alteplase to Tenecteplase. Neurotherapeutics, 2023, 20, 664-678.	4.4	1
118	Tenecteplase: A Review of Its Pharmacology and Uses. AACN Advanced Critical Care, 2023, 34, 77-83.	1.1	0
119	ST-elevation myocardial infarction after thrombolytic therapy with Tenecteplase for acute ischaemic stroke. BMJ Case Reports, 2023, 16, e252253.	0.5	1
120	Intravenous Thrombolysis in Acute Ischemic Stroke. , 0, , .		0
121	Tenecteplase Versus Alteplase for Acute Stroke: Mortality and Bleeding Complications. Annals of Emergency Medicine, 2023, 82, 720-728.	0.6	4
122	Tenecteplase real-world data: A three phase sequential comparison. European Stroke Journal, 2023, 8, 942-946.	5.5	2
123	Tenecteplase vs. Alteplase for Intravenous Thrombolytic Therapy of Acute Ischemic Stroke: A Systematic Review and Meta-Analysis. Neurology and Therapy, 2023, 12, 1553-1572.	3.2	3
124	Tenecteplase versus alteplase for acute ischaemic stroke: a meta-analysis of phase III randomised trials. Stroke and Vascular Neurology, 0, , svn-2023-002396.	3.3	1
125	Management and Prognosis of Acute Stroke in Atrial Fibrillation. Journal of Clinical Medicine, 2023, 12, 5752.	2.4	2
126	Clinical Policy: Critical Issues in the Management of Adult Patients Presenting to the Emergency Department With Acute Ischemic Stroke. Annals of Emergency Medicine, 2023, 82, e17-e64.	0.6	2
128	A Comparative Study of Hemorrhagic Conversion Patterns After Stroke Thrombolysis With Alteplase Versus Tenecteplase. Cureus, 2023, , .	0.5	0
129	Medical Management of Acute Cerebral Ischemia. Delaware Journal of Public Health, 2023, 9, 20-26.	0.3	1
130	Tenecteplase, 0.4 mg/kg, in Moderate and Severe Acute Ischemic Stroke: A Pooled Analysis of NORâ€ŢEST and NORâ€ŢEST 2A. Journal of the American Heart Association, 2023, 12, .	3.7	0
131	Moving From Alteplase to Tenecteplase for Acute Ischemic Stroke—Mayo Clinic Experience. Neurologist, 0, , .	0.7	0

#	Article	IF	CITATIONS
132	The efficacy and safety of tenecteplase compared with alteplase in adult patients with acute ischemic stroke: an updated systematic review and meta-analysis of ten randomized controlled trials. Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2023, 59, .	1.0	0
133	Management of acute ischemic stroke. Medicina ClÃnica (English Edition), 2023, 161, 485-492.	0.2	0
134	Tenecteplase versus Alteplase in Acute Ischemic Stroke: A Systematic Review and Meta-analysis. Annals of Neurosciences, $0, \dots$	1.7	0
135	Thrombolysis with Recombinant Human Prourokinase 4.5–6 h After Acute Ischemic Stroke: A Phase IIa, Randomized, and Open-Label Multicenter Clinical Trial. CNS Drugs, 0, , .	5.9	0
136	Tenecteplase versus alteplase for patients with acute ischemic stroke: a meta-analysis of randomized controlled trials. Aging, 2023, 15, 14889-14899.	3.1	1
137	Tenecteplase for Acute Ischemic Stroke Thrombolysis. Neurology: Clinical Practice, 2024, 14, .	1.6	0
138	Perioperative stroke. Nature Reviews Disease Primers, 2024, 10, .	30.5	0
139	Comparison of pharmacokinetic properties of alteplase and tenecteplase. The future of thrombolysis in acute ischemic stroke. Expert Opinion on Drug Metabolism and Toxicology, 2024, 20, 25-36.	3.3	0
140	Quality of Life After Intravenous Thrombolysis for Acute Ischemic Stroke: Results From the AcT Randomized Controlled Trial. Stroke, 2024, 55, 524-531.	2.0	0
141	Tenecteplase thrombolysis for stroke up to 24 hours after onset with perfusion imaging selection: the umbrella phase IIa CHABLIS-T randomised clinical trial. Stroke and Vascular Neurology, 0, , svn-2023-002820.	3.3	1
142	Outcomes associated to the time to treatment with intravenous tenecteplase for acute ischaemic stroke: subgroup analysis of the TRACE-2 randomised controlled clinical trial. Stroke and Vascular Neurology, 0, , svn-2023-002694.	3.3	0
143	Advances in neurovascular research: Scientific highlights from the 15th world stroke congress. Journal of Stroke and Cerebrovascular Diseases, 2024, 33, 107617.	1.6	0
145	Efficacy and safety outcomes of Tenecteplase versus Alteplase for thrombolysis of acute ischemic stroke: A meta-analysis of 9 randomized controlled trials. Journal of the Neurological Sciences, 2024, 458, 122912.	0.6	0
146	Tenecteplase versus alteplase for acute ischemic stroke: a systematic review and meta-analysis of randomized and non-randomized studies. Journal of Neurology, 2024, 271, 2309-2323.	3.6	0
147	Tenecteplase versus alteplase for the treatment of acute ischemic stroke: a meta-analysis of randomized controlled trials. Annals of Medicine, 2024, 56, .	3.8	0
148	Fibrinolytic Agents in Thromboembolic Diseases: Historical Perspectives and Approved Indications. Seminars in Thrombosis and Hemostasis, 0, , .	2.7	O